NHS

**The Clatterbridge
Cancer Centre**

NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 14 July 2022

**Re: Freedom of Information Request
Ref: 209-2022**

Thank you for your email dated the 22/06/2022, requesting information in relation to breast cancer treatment.

The information you require is as follows:

**Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
(December 21 - February 22)**

Abemaciclib + Aromatase Inhibitor	0
Abemaciclib + Fulvestrant	19
Anthracycline	1
Atezolizumab + Nab-paclitaxel	0
Atezolizumab + Paclitaxel	0
Capecitabine	62
Carboplatin	7
Cisplatin	0
Eribulin	16
Everolimus + Exemestane	0
Fulvestrant	15
Lapatinib	0
Neratinib	7
Parp Inhibitors	0
Palbociclib + Aromatase Inhibitor	0
Palbociclib + Fulvestrant	39
Pembrolizumab	0
Pertuzumab + Trastuzumab + Docetaxel	0

Ribociclib + Aromatase Inhibitor	0
Ribociclib + Fulvestrant	3
Sacituzumab Govitecan	0
Taxane	261
Trastuzumab	257
Trastuzumab + Emtansine	0
Transtuzumab + Deruxtecan	17
Vinorelbine	9

- **Any other active systemic anti-cancer therapy:**

Abemaciclib	33
Aspirin/placebo (ADD Aspirin Trial)	6
Atezolizumab	3
Atezolizumab + Paclitaxel + Albumin	5
Carboplatin + Paclitaxel	34
Cyclophosphamide + Docetaxel	6
Denosumab	424
Docetaxel + Phesgo	7
Doxorubicin	2
Doxorubicin Cyclophosphamide	1
Epirubicin	6
Epirubicin Cyclophosphomide	190
Everolimus	15
Faslodex	35
Gemcitabine + Carboplatin	4
Ibandronate	2
Letrozole	5
Paclitaxel + Pertuzumab + Trastuzumab	58
Palbociclib	254
Pertuzumab	4
Pertuzumab + Trastuzumab	11
Phesgo	147
Ribociclib	10
Zoladex	323
Zoledronate	806

Q2. In the past 3 months, how many early/locally advanced breast cancer (Stages 1 to 3B) patients were treated with:

- **Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) - 0**
- **Taxane and/or Anthracycline (monotherapy or in combination) - 18**
- **Any other active systemic anti-cancer therapy:**

Abemaciclib	5
Abemaciclib + Fulvestrant	3

Capecitabine	14
Carboplatin + Paclitaxel	1
Denosumab	138
Doxorubicin Cyclophosphamide	1
Epirubicin Cyclophosphomide	2
Eribulin	1
Everolimus	4
Faslodex	9
Fulvestrant	2
Gemcitabine + Carboplatin	1
Letrozole	2
Paclitaxel + Pertuzumab + Trastuzumab	2
Palbociclib	70
Palbociclib + Fulvestrant	6
Pertuzumab	2
Pertuzumab + Trastuzumab	4
Phesgo	28
Ribociclib	3
Transtuzumab + Deruxtecan	6
Trastuzumab	33
Vinorelbine	4
Zoladex	28
Zoledronate	6

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be

addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

https://www.surveymonkey.co.uk/r/H39RFMM

Kind Regards,

The Information Governance Team
Contact Email: ccf-tr.foi@nhs.net